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We are interested in the estimation of average treatment effects based on right-censored data of an
observational study. We focus on causal inference of differences between t-year absolute event risks
in a situation with competing risks. We derive doubly robust estimation equations and implement
estimators for the nuisance parameters based on working regression models for the outcome, the
censoring and the treatment distribution conditional on auxiliary baseline covariates. We use the
functional delta method to show that our estimators are regular asymptotically linear estimators
and estimate their variances based on estimates of their influence functions. In empirical studies
we assess the robustness of the estimators and the coverage of confidence intervals. The methods
are further illustrated using data from a Danish registry study.
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1 Introduction
Average treatment effects (ATE) are important parameters in epidemiology (Robins, 1986; Hernán
and Robins, 2006). In observational studies, these parameters are interpreted in a suitable frame-
work for causal inference (Hernán and Robins, 2019; Pearl, 2000) as what one would have observed
had the treatment been randomized. Estimators of average treatment effects include outcome re-
gression model based estimators which standardize the expected outcome to a given distribution of
the confounders (G-formula), inverse probability of treatment weighted (IPTW) estimators which
rely on a model for the propensity of treatment, and doubly robust estimators which combine the
two types of estimators with the aim to reduce bias (van der Laan and Robins, 2003; Kang et al.,
2007; Glynn and Quinn, 2010).
In this article, we are motivated by applications in pharmacoepidemiology where the aim is to
evaluate differences between alternative drug treatments based on large scale registry data (Hernán
and Robins, 2016). We are particularly interested in applications where the outcome is a right
censored time to event and death without the outcome is a competing risk. We restrict our discussion
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to the simple setting where a treatment decision is made only once at baseline and all patients are
supposed to stay on treatment for a pre-specified amount of time, say until τ -years after initiation of
the treatment. We then consider treatment differences between the absolute τ -year risks of an event
of interest as the main target parameter and aim to achieve an interpretation in the counterfactual
world where the treatment is randomized.
Compared to other approaches for competing risk data (Andersen et al., 2017; Bekaert et al.,
2010; Moodie et al., 2014), the major difference of our approach is that we use working Cox regression
models for the cause-specific hazard rates to estimate the absolute risk of the event (Benichou and
Gail, 1990; Ozenne et al., 2017). Furthermore, we allow the censoring distribution to depend on
baseline covariates via a separate Cox regression model and work with a logistic regression model for
the propensity of treatment. We study the robustness of our estimator to a possible misspecification
of any of these working models. Our work relates and extends recent developments in survival
analysis: Wang et al. (2016) proposed a doubly robust estimator for right-censored survival data
when using parametric working regression models for the outcome distribution and the treatment
distribution, and a non-parametric model (Kaplan Meier) for the censoring distribution. Using the
semiparametric theory (Bickel et al., 1993; van der Laan and Robins, 2003; Tsiatis, 2006), we derive
an augmentation term which makes our estimator robust against misspecification of the censoring
model. The augmentation term resembles the one in the survival case (Zhao et al., 2014). We also
derive the influence function of our estimator and show that it can be greatly simplified when all
working models are correctly specified.
This paper is structured as follows: Section 2 formally introduces the competing risk setting,
the parameter of interest, and the statistical models. Section 3 presents the G-formula, IPTW,
and doubly robust estimators in a competing risk setting. We derive in section 4 the asymptotic
properties of our three estimators: consistency, asymptotic normality, and their influence function.
Robustness of the estimators to model misspecification and coverage of confidence intervals based
on the asymptotic distribution of the estimators is assessed in section 5 using simulation studies.
Finally, in section 6, we apply our estimators to compare two anticoagulation treatments regarding
their impact on the risk of bleeding (adverse endpoint) in patients with atrial fibrillation. The
data used for this illustration are a subset of the data of Stærk et al. (2018), where we applied
Cox regression for the event hazard and the hazard of death without event in order to estimate
average differences in τ -year risk of stroke and bleeding between alternative drugs for anticoagulation
therapy.
2 Competing risk setting
2.1 Notation and parameter of interest
We consider a random sample of n individuals {(T˜i, ∆˜i, Ai,Wi)}ni=1 where A is a binary treatment
variable assigned at baseline,W a d-dimensional vector of auxiliary covariates measured at baseline,
T˜ a right-censored event time, i.e., T˜ = T ∧ C where T is the event time, C the censoring time, ∆
is the event type for which we assume that {∆ = 1} means that the event of interest occurred and
{∆ = 2} that the competing event occurred, and ∆˜ = ∆1{T ≤ C} indicates uncensored observation
(we use 1{·} to denote the indicator function). We assume throughout that (T,∆) are conditionally
independent of C given (W,A) and that in the case of tied event and censoring times, i.e., C = T , the
event time is earlier. Also, for a fixed time point τ we assume that the probability of right-censoring
is bounded away from zero: P[C > τ |A,W ] >  where  > 0. We denote Y (τ) = 1{T ≤ τ,∆ = 1}
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for the indicator for the event of interest at time τ and note that its expected value is the absolute
risk that the event of interest occurs before time τ .
To define our target parameter we introduce the potential outcomes Y a(τ), i.e., the response
of a randomly selected individual had that individual, possibly contrary to the fact, been given
treatment A = a. Our target parameter is the expected difference:
Ψ(τ) = E[Y 1(τ)− Y 0(τ)].
We make the following assumptions: Y (τ) = (1 − A)Y 0(τ) + AY 1(τ) (consistency assumption),
∀a ∈ {0, 1}, (Y a(τ), A) are conditionally independent given W , (no unmeasured confounders), and
∀(a,w) ∈ {0, 1} × W, P[A = a|w] > 0 (positivity assumption) where W ⊂ Rd denotes the set of
possible values for W .
2.2 Modeling
To estimate the target parameter based on the observed data we consider the following conditional
distributions as nuisance parameters. The cumulative incidence function F1 describes the absolute
risk of the event of interest by time t:
F1(t|A,W ) = P(T ≤ t,∆ = 1|A,W ),
G is the conditional probability of being uncensored
G(t|A,W ) = P(C > t|A,W ),
and pi describes the propensity of treatment conditional on W
pi(W ) = P(A = 1|W ).
Under the identifiability assumptions stated in section 2.1 the likelihood of the observed variables
Oi = (T˜i, ∆˜i, Ai,Wi) factorizes (Begun et al., 1983; Gill et al., 1995) and the density of their joint
probability distribution P with respect to a suitable dominating measure can be parametrized
P(dt, δ, a, dw) = {G(t− |a,w)F1(dt|a,w)(api(w) + (1− a)(1− pi(w))H(dw)}1{δ=1}
{G(t− |a,w)F2(dt|a,w)(api(w) + (1− a)(1− pi(w))H(dw)}1{δ=2}
{S(t− |a,w)G(dt|a,w)(api(w) + (1− a)(1− pi(w))H(dw)}1{δ=0}
where F2(t|A,W ) = P(T ≤ t,∆ = 2|A,W ), H is the marginal distribution of W , and t− denotes
the left-handed limit at time t. Our working model for the joint probability distribution P leaves
the H part completely non-parametric but for each of the other nuisance parameters we specify
a (semi-)parametric regression model as our working model and define a corresponding estimator.
Our working model for F1 uses the parameterization of Benichou and Gail (1990) in terms of the
cumulative cause-specific hazard functions Λ1 for the event of interest and Λ2 for the competing
event:
F1(t|A,W ) =
∫ t
0
S(s− |A,W )Λ1(ds|A,W ) (1)
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where S(s|A,W ) = exp {−(Λ1(s|A,W ) + Λ2(s|A,W ))} is the event free survival function. Specifi-
cally we consider two separate Cox regression models for Λ1 and Λ2 such that the model is param-
eterized in terms of the cause-specific hazard ratios and baseline hazard functions. An alternative
parameterization of F1 can be obtained by binomial regression for competing risks (Scheike et al.,
2008) where the Fine-Gray regression model (Fine and Gray, 1999) is a special case. Our working
models for the censoring mechanism and the propensity of treatment are a Cox regression model and
a logistic regression model, respectively. Note that all these working models come with their reg-
ular asymptotically linear estimators for the respective nuisance parameter based on the observed
data. Thus, we assume that there exist regular asymptotically linear estimators Fˆ1n, pˆin, Sˆn, Gˆn
with respective large sample limits F ∗1 , pi∗, S∗, G∗ such that:
√
n(pˆin − pi∗) = 1√
n
n∑
i=1
IFpi∗(Oi) + op(1),
√
n(Gˆn −G∗) = 1√
n
n∑
i=1
IFG∗(Oi) + op(1),
√
n(Fˆ1n − F ∗1 ) =
1√
n
n∑
i=1
IFF∗1 (Oi) + op(1),
√
n(Sˆn − S∗) = 1√
n
n∑
i=1
IFS∗(Oi) + op(1),
(2)
where Oi = (T˜i, ∆˜i, Ai,Wi) and IFF∗1 , IFpi∗ , IFS∗ , IFG∗ are the influence functions corresponding to
the estimators that represent the first order von Mises expansion of the corresponding statistical
functional (van der Vaart, 1998). If our working model for F1 is correctly specified then the
asymptotic bias is zero, F ∗1 − F1 = 0, and the same holds for the working models for pi, S and G.
Note that since both F1 and S can be expressed as differentiable functionals of Λj for j = 1, 2, a
sufficient condition for the last two lines of equation (2) is
√
n(Λj − Λ∗j ) =
1√
n
n∑
i=1
IFΛ∗
j
(Oi) + op(1),
where IFΛ∗
j
is the influence function of the Cox regression estimator of the cumulative hazard
function j and Λ∗j is the corresponding large sample limit.
In case of a misspecified model, an asymptotic linear expansions of the estimators as in equation
(2) still continues to hold under the usual regularity conditions around the least-false parameters
F ∗1 , pi
∗, S∗, G∗ (White, 1982; Hjort, 1992; Bickel et al., 1993; Gerds and Schumacher, 2001). However,
there would be a large sample bias.
3 Estimators for the average treatment effect (ATE)
We consider three types of estimators for our estimand Ψ(τ). Each type is based on a different
combination of the outcome model, the treatment model, and the censoring model. We start by
defining our estimators in the case without censoring.
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3.1 Uncensored data
The first class of estimators is based on the G-causal parameter (Robins (1986), p.1410), also called
backdoor adjustment (Pearl (2000), section 3.2), which yields the G-formula:
Ψ(τ) = E[F1(τ |A = 1,W ))− F1(τ |A = 0,W )].
Our regression estimator is obtained by substituting Fˆ1n for F1:
Ψ̂G-formula(τ) =
1
n
n∑
i=1
(
Fˆ1n(τ |A = 1,Wi)− Fˆ1n(τ |A = 0,Wi)
)
. (3)
The second class of estimators uses inverse probability-of-treatment weights (IPTW) and is based
on the formula:
Ψ(τ) = E
[
Y (τ)
(
A
pi(W ) −
1−A
1− pi(W )
)]
.
Our IPTW estimator is obtained by substituting pˆin for pi:
Ψ̂IPTW(τ) =
1
n
n∑
i=1
(
Yi(τ)
(
Ai
pˆin(Wi)
− 1−Ai1− pˆin(Wi)
))
. (4)
The third class of estimators combines the G-formula estimator and the IPTW estimator into a
doubly robust estimator (Hernán and Robins, 2019). Following Tsiatis (2006) (section 13.5) we use
the formula
Ψ(τ) = E
[
Y (τ)A
pi(W ) + F1(τ |A = 1,W )
(
1− A
pi(W )
)
−Y (τ)(1−A)1− pi(W ) − F1(τ |A = 0,W )
(
1− 1−A1− pi(W )
)]
.
Our augmented IPTW estimator (denoted AIPTW) substitutes pˆin for pi and Fˆ1n for F1:
Ψ̂AIPTW(τ) =
1
n
n∑
i=1
Yi(τ)Ai
pˆin(Wi)
+ Fˆ1n(τ |A = 1,Wi)
(
1− Ai
pˆin(Wi)
)
− Yi(τ)(1−Ai)1− pˆin(Wi) − Fˆ1n(τ |A = 0,Wi)
(
1− 1−Ai1− pˆin(Wi)
)
. (5)
We refer to Glynn and Quinn (2010) and Kennedy (2016) for nice reviews of the doubly robust
AIPTW estimator in uncensored data.
3.2 Right-censored data
In presence of right-censoring, the binary outcome at the time point of interest Y (τ) is not observed
for all subjects, it is only observed in the event {C > T ∧ τ} = {T˜ > τ} ∪ {T˜ ≤ τ, ∆˜ 6= 0}. To
construct estimators of the average treatment effect based on the right-censored data, we combine
the estimators of the previous section with inverse probability-of-censoring weighting (IPCW) now
© 0 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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also using our estimator Gˆn. Note that the G-formula estimator defined in equation (3) does not
explicitly involve Y (τ) and hence can be applied directly in right-censored data because the outcome
model takes care of the censored data. Using that 1{T˜ > τ}Y (τ) = 0, we define the following IPCW
estimators:
Ψ̂IPTW,IPCW(τ) =
1
n
n∑
i=1
1{T˜i ≤ τ, ∆˜i 6= 0}
Gˆn(T˜i|Ai,Wi)
Yi(τ)
(
Ai
pˆin(Wi)
− 1−Ai1− pˆin(Wi)
)
(6)
Ψ̂AIPTW,IPCW(τ) =
1
n
n∑
i=1
1{T˜i ≤ τ, ∆˜i 6= 0}
Gˆn(T˜i|Ai,Wi)
Yi(τ)Ai
pˆin(Wi)
+ Fˆ1n(τ |A = 1,Wi)
(
1− Ai
pˆin(Wi)
)
− 1{T˜i ≤ τ, ∆˜i 6= 0}
Gˆn(T˜i|Ai,Wi)
Yi(τ)(1−Ai)
1− pˆin(Wi) − Fˆ1n(τ |A = 0,Wi)
(
1− 1−Ai1− pˆin(Wi)
)
. (7)
Both estimators can now be augmented using semi-parametric theory (see van der Laan and Robins
(2003)). In appendix A, we derive the set of observed-data estimating functions for Ψ. These
estimating equations include an augmentation term which, when set to 0, leads to the IPCW
estimators (equations (6) and (7)). Alternatively the augmentation term can be chosen in order to
minimize the asymptotic variance of the corresponding estimator. This choice lead to the following
estimators (see appendix A for details):
Ψ̂IPTW,AIPCW(τ) = Ψ̂IPTW,IPCW(τ) +
1
n
n∑
i=1
Iˆ(T˜i, τ |Ai,Wi)
(
Ai
pˆin(Wi)
− 1−Ai1− pˆin(Wi)
)
(8)
Ψ̂AIPTW,AIPCW(τ) = Ψ̂AIPTW,IPCW(τ) +
1
n
n∑
i=1
Iˆ(T˜i, τ |Ai,Wi)
(
Ai
pˆin(Wi)
− 1−Ai1− pˆin(Wi)
)
(9)
where Iˆ(T˜i, τ |Ai,Wi) =
∫ T˜i∧τ
0
Fˆ1n(τ |Ai,Wi)− Fˆ1n(t|Ai,Wi)
Sˆn(t|Ai,Wi)
1
Gˆn(t|Ai,Wi)
dMˆCi (t).
Here NCi (t) = 1{T˜i ≤ t, ∆˜i = 0} denotes the censoring counting process of subject i and ΛC the
cumulative hazard function of G such thatMCi (t) = NCi (t)−
∫ t
0 1{T˜i ≥ s}ΛC(ds|Ai,Wi) is a 0 mean
process (a martingale with respect ot the natural filtration, see for example Andersen et al., 1993,
section II.4). We use the notation MˆCi (t) = NCi (t) −
∫ t
0 1{T˜i ≥ s}ΛˆC(ds|Ai,Wi) and MC,∗i (t) =
NCi (t)−
∫ t
0 1{T˜i ≥ s}ΛC,∗(ds|Ai,Wi) where ΛC,∗ is the large sample limit of ΛˆC .
4 Asymptotic properties
In this section, we study the asymptotic properties of the following estimators: Ψ̂G-formula(τ),
Ψ̂IPTW,IPCW(τ), and Ψ̂AIPTW,AIPCW(τ).
4.1 Consistency
By equation (2) and the law of large numbers we have
lim
n→∞ Ψ̂G-formula(τ) = E[F
∗
1 (τ |A = 1,W ))− F ∗1 (τ |A = 0,W )].
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Thus, if the outcome model is correctly specified at τ , i.e., for a ∈ {0, 1} and almost all w
F1(τ |a,w) = F ∗1 (τ |a,w), then Ψ̂G-formula is a consistent estimator for Ψ(τ). Similarly, we have
under the assumptions of Section 2
lim
n→∞ Ψ̂IPTW,IPCW(τ) = E
[ G(T˜ |A,W )
G∗(T˜ |A,W )
{F1(τ |A = 1,W )pi(W )
pi∗(W ) .
− F1(τ |A = 0,W )(1− pi(W ))1− pi∗(W )
}]
Hence, if the working models for the treatment and the censoring mechanism are correctly specified,
i.e., pi(w) = pi∗(w) and G(s|a,w) = G∗(s|a,w) for all s ∈ [0, τ ], a ∈ {0, 1} and almost all w,
then Ψ̂IPTW,IPCW(τ) is consistent. The following theorem states sufficient conditions under which
Ψ̂AIPTW,AIPCW is consistent.
Theorem 1 Under the assumptions stated in Section 2, the estimator Ψ̂AIPTW,AIPCW(τ) is con-
sistent whenever one of the following conditions is satisfied for all s ∈ [0, τ ], a ∈ {0, 1} and almost
all w:
1. G∗(s|a,w) = G(s|a,w) and F ∗1 (τ |a,w) = F1(τ, a, w)
2. G∗(s|a,w) = G(s|a,w) and pi∗(w) = pi(w)
3. F ∗1 (s|a,w) = F1(s|a,w) and S∗(s|a,w) = S(s|a,w)
Proof: Roughly, when the censoring model is correctly specified, 1. and 2. follow from the
fact that Ψ̂AIPTW,AIPCW(τ) and Ψ̂AIPTW(τ) have the same large sample limit. When the cen-
soring model is misspecified but the outcome and survival models are correctly specified then
Ψ̂AIPTW,AIPCW(τ) and Ψ̂G-formula(τ) have the same large sample limit, which gives 3. Appendix B
provides the details.
4.2 Asymptotic distribution
All estimators described in the previous section can be written as averages of the estimated nuisance
parameters:
Ψ̂x(τ) =
1
n
n∑
i=1
hx(τ ;Oi; Fˆ1n, pˆin, Sˆn, Gˆn)
where x ∈{G-formula; IPTW,IPCW;AIPTW,IPCW; IPTW,AIPCW;AIPTW,AIPCW}
and a suitable function hx. For instance,
hG-formula(τ ;Oi; Fˆ1n, pˆin, Sˆn, Gˆn) = Fˆ1n(τ |A = 1,Wi)− Fˆ1n(τ |A = 0,Wi).
If the nuisance parameters were known, say equal to (F ∗1 , pi∗, S∗, G∗), the correspondingly defined
plug-in estimators would be simple averages of independent and identically distributed quantities
with influence function:
I˜Fx(τ ;Oi) = hx(τ ;Oi;F ∗1 , pi∗, S∗, G∗)−Ψ∗x(τ) (10)
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where Ψ∗x is the large sample limit of Ψ̂x. From the central limit theorem, we would get that
the estimators are asymptotically normal with asymptotic variance equal to the variance of the
influence function. However, in practice the nuisance parameters are estimated with the same data
and the asymptotic expansions of the estimators of the average treatment effect involve the influence
functions of the estimators of the nuisance parameters given in equation (2). The general idea is
to apply the functional delta method (van der Vaart (1998), chapter 20) to obtain a von Mises
expansion of the form:
√
n(Ψ̂x(τ)−Ψ∗x(τ)) =
1√
n
n∑
i=1
IFx(τ ;Oi) + oP (1).
The influence function has two terms:
IFx(τ ;Oi) = I˜Fx(τ ;Oi) + φx(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗) (11)
where a function φx (the derivate of hx) relates to the influence functions of the estimators of the
nuisance parameters. In the case of the G-formula estimator,
φG-formula(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗) = E[IFF∗1 (τ,A = 1,W ;Oi)|Oi]
− E[IFF∗1 (τ,A = 0,W ;Oi)
∣∣Oi]
and for the IPTW, IPCW estimator:
φIPTW,IPCW(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗)
=− E
[
IFpi∗(W ;Oi)
1{T˜ ≤ τ, ∆˜ 6= 0}
G∗(T˜ |A,W ) Y (τ)
(
A
pi∗(W )2 +
1−A
(1− pi∗(W ))2
)∣∣∣∣∣Oi
]
(12)
− E
[
IFG∗(T˜ , A,W ;Oi)
1{T˜ ≤ τ, ∆˜ 6= 0}
G∗(T˜ |A,W )2 Y (τ)
(
A
pi∗(W ) −
1−A
1− pi∗(W )
) ∣∣∣∣∣Oi
]
. (13)
The formula for the influence function of Ψ̂AIPTW,AIPCW is more complex and can be found in
Appendix C.
Under the assumptions stated in Section 2, and in particular under equation (2), the functional
delta method yields that the asymptotic distribution of the estimator Ψ̂x is a normal distribution
with variance equal to the variance of the influence function. The variance of Ψ̂x can then be
estimated based on an estimate ÎFx of the influence function: 1n
∑n
i=1
(
ÎFx(Oi)
)2.
Remark 1: In appendix C we show that when all working models are correctly specified, then
we have φAIPTW,AIPCW(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗) = 0. In this case a consistent estimator of the
asymptotic variance of Ψ̂AIPTW,AIPCW(τ) is given by
1
n
n∑
i=1
(
Fˆ1n(τ |A = 1,Wi)− Fˆ1n(τ |A = 0,Wi)− ΨˆAIPTW,AIPCW(τ)
+
(
Ai
pˆin(Wi)
− 1−Ai1− pˆin(Wi)
)(
1{T˜i ≤ τ, ∆˜i 6= 0}Yi(τ)
Gˆn(T˜i|Ai,Wi)
− Fˆ1n(τ |Ai,Wi) + Iˆ(T˜i, τ |Ai,Wi)
))2
.
This result is a consequence of the orthogonality between the estimating function and the nuisance
parameter tangent space, see also Tsiatis (2006, Remark 4, Section 3.3).
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5 Empirical studies
The following simulation studies investigate the bias-variance tradeoff of the various estimators
under model misspecification and the small sample coverage based on the asymptotic variance
formula.
5.1 Simulation setting
In total, 12 auxiliary covariates are simulated, 6 having a standard normal distribution (W1, . . . ,W6)
and the remaining 6 having a Bernoulli distribution (W7, . . . ,W12). A binary treatment variable is
drawn following a logistic regression model. We use three Cox-Weibull regression models (Table II,
Bender et al., 2005) to simulate three latent times conditional on treatment and auxiliary covariates,
one for the event of interest, one for the competing risk and one for the right-censoring time. The
observed time is then obtained as the minimum of the three latent times and the event status
corresponds to the event with the smallest latent time. In the main analyses the 12 auxiliary
covariates are independent. The covariate effects on the treatment, hazard rate of the event of
interest, the hazard rate of the competing risk and the hazard rate of the censoring are controlled
by including additive effects of the 6 binary variables, the 6 continuous variables and the squares of
the 6 continuous variables into the linear predictors of the logistic regression and the Cox-Weibull
regression models, respectively. The effect of treatment on the three hazard rates is controlled by
three additional regression parameters. Note that the randomized world corresponds to setting all
regression parameters of the logistic regression model to zero and deviations from the randomized
world can be controlled by varying these covariate effects (Figure 1).
[Figure 1 about here.]
For various parameter settings we report results of the estimators G-formula (equation 3),
IPTW, IPCW (equation 6), and AIPTW,AIPCW (equation 9) across 1,000 simulated datasets.
These estimators are implemented in R (R Core Team, 2018) in the package riskRegression (Gerds
and Ozenne (2019), function ateRobust). When estimating the variance of the AIPTW,AIPCW es-
timators, we consider two estimators for the influence function. The first, denoted I˜FAIPTW,AIPCW,
only estimates the first term of equation (11) since the second term is 0 in correctly specified
models. The second estimates both terms and is denoted IFAIPTW,AIPCW. However we have not
implemented all the terms necessary to compute φAIPTW,AIPCW: the current implementation is
equivalent to neglecting the uncertainty relative to the censoring weights and the augmentation
term I(T˜ , τ |A,W ). The R-code of our simulation studies is available as supplementary material.
5.2 Simulation results
We report results for a data generating model without treatment effect (Panel A, Figure 1). The
figure shows Aalen-Johansen estimates (Aalen and Johansen, 1978; Andersen et al., 1993) of the
cumulative incidence functions. Similar results are obtained when considering a non-zero treatment
effect but then the “true” value needs to be obtained empirically. Model misspecification is simu-
lated by omitting covariates and quadratic effects. We created four scenarios. In the first one, all
models are correctly specified. In the three other scenarios, precisely one of the censoring, outcome,
or treatment models is misspecified. As shown in figure 2 (upper panel), the AIPTW,AIPCW esti-
mator is consistent even when one of the models (outcome, treatment, or censoring) is misspecified.
The G-formula estimator and the IPTW,IPCW estimator need one or two models to be correctly
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specified to be consistent - the outcome model for the G-formula estimator and both the treatment
and censoring models for the IPTW,IPCW estimator. The G-formula estimator appears to be less
variable compared to the other estimators. The IPTW,IPCW estimator is at least as variable but
often more variable than the AIPTW,AIPCW estimator. The coverage of the G-formula estimator
and AIPTW,AIPCW estimator is found satisfactory even in small samples when the outcome model
is correctly specified (Figure 3).
[Figure 2 about here.]
[Figure 3 about here.]
6 Real data application
For the sole purpose of illustration, we consider a subset of the data presented in Stærk et al.
(2018). This Danish registry study included n=21149 patients with a diagnosis of atrial fibrillation
(AF) in the period 2012-2016 who initiated anticoagulation treatment with a standard dose of
dabigatran (n=7078) or rivaroxaban (n=6868) or apixaban (n=7203). All three treatments belong
to the group of non-vitamin K antagonist oral anticoagulants (NOAC’s). Here we consider only
data from patients that initiated treatment with either dabigatran or rivaroxaban. The follow up
started at the date of treatment initiation. The original study Stærk et al. (2018) presented results
on several adverse endpoints including thromboembolism/stroke and major bleeding where death
without the endpoint is the only competing risk. Here we consider the analysis of the endpoint
major bleeding where death without major bleeding or shift or discontinuation of treatment are the
competing risk. The treatment assignment is not randomized but there are official guidelines and
presumably also doctor preferences which most likely also depend on the patient characteristics.
Note that the results presented here for G-formula are not directly comparable to those presented
in Stærk et al. (2018) because we here restrict all Cox regression models to the subset of the
dabigatran and rivaroxaban patients. Otherwise we use the same covariate adjustment as described
in detail in Stærk et al. (2018) for all Cox regression models and for the logistic regression model of
the treatment mechanism. Figure 4 displays the estimates absolute risk of major bleeding obtained
with G-formula and AIPTW,AIPCW. Within the limitation of the available confounder information
the results can be interpreted as what one would have observed in a hypothetical world where all
patients initiated dabigatran (or rivaroxaban), respectively.
The interpretation of these results is limited to the population of patients who initiated either
dabigatran or rivaroxaban in the period 2012-2016. Based on the AIPTW,AIPCW estimate evalu-
ated at 12 months, the interpretation could be as follows. If every patient had received dabigatran
the 1-year risk [95% confidence interval] of a major bleeding would have been 1.58% [0.60;2.57] lower
compared to when every patient had received rivaroxaban. Interestingly, the AIPTW,AIPCW es-
timates of the risk differences are larger in magnitude compared to the G-formula estimates. For
example, the estimate of ATE (12-month) using G-formula is only 0.97% [0.40;1.54].
[Figure 4 about here.]
7 Discussion
In presence of completely observed outcomes, estimation of the average treatment effect can be
performed using estimators based on the G-formula, inverse probability of treatment weighting
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(IPTW), or a combination of both (AIPTW). While these are classical tools in causal inference
(see for e.g., part 2 of Hernán and Robins (2019)), we review in this article their extension to right-
censored data and to the presence of competing risks. Using results from semi-parametric theory,
we derive the augmentation term relative to the working model for the censoring distribution. We
investigate the robustness of this new estimator against misspecification of the working models.
We also show the asymptotic normality of this estimator and derive an analytical formula for its
influence function which can be used to estimate the variance of the estimator. The variance of our
estimator may depend on the estimators of the nuisance parameters. In our software implementation
(Gerds and Ozenne, 2019), we focus on the use of cause-specific Cox regression models for the
outcome model, a logistic regression for the treatment model, and a Cox regression model for the
censoring model. An alternative would be to use a Fine-Gray regression model for the outcome.
However, then one would need an additional working regression model for the conditional event-
free survival function S(·|A,W ). To simplify the implementation, we currently do not estimate the
variability related to the estimation of the censoring distribution G(·|A,W ) and the augmentation
term I(·, τ |A,W ). In to our simulation study this omission did not have a large effect and the
coverage of our confidence intervals was sufficient.
The simulations confirm the superiority of the AIPTW,AIPCW estimator over the IPTW, IPCW
estimator. They also show that the G-formula estimator is less variable than the AIPTW,AIPCW
estimator when the outcome model is correctly specified. However, the G-formula estimator has a
bias that the AIPTW,AIPCW estimator does not have when the outcome model is misspecified. It
is worth noting that the definition of the G-formula estimator is unchanged in presence of censoring
- only the outcome model has to properly handle censoring.
Competing risks essentially lead to a change of the definition of the outcome, where we use
1{T ≤ τ,∆ = 1} instead of 1{T ≤ τ}. However one should not overlook that the presence of com-
peting risks complexifies the assessment of the treatment effect, especially when the treatment has
a positive effect on the cause of interest but a negative effect on the competing events. We refer to
Young et al. (2018) for a detailed discussion of the implications of how the estimand is defined in
presence of competing risks.
Recently, Lesko and Lau (2017) pointed out that bias will occur if we do not have the correct mod-
els for the probability of the outcome of interest F1(τ |A,W ) = P[T ≤ τ,∆ = 1|A,W ], in particular
when the model for the hazard rate of the competing risk Λ2 is misspecified. In practice this means
that, if we estimate the outcome model via a cause-specific Cox regression models, both conditional
hazard functions need to be correctly specified. While our approach relies on prior knowledge to
define the working models, automated techniques and the use of cross-validation (Benkeser et al.,
2018) may be preferable when prior knowledge is sparse. Indeed, the Cox regression model makes
the assumption of proportional hazards which may not always be appropriate. This assumption can
be relaxed, e.g., by using stratified baseline hazard functions, time varying coefficients (Martinussen
and Scheike, 2007), or an alternative approach that does not rely on this assumption (e.g., using
pseudo-observations (Andersen et al., 2017)).
We have focused on a binary treatment variable. In the case of a multi-valued treatment variable
the several estimands can be defined depending on the type of the treatment variable (ordinal versus
nominal), see Imbens (2000) for a nice discussion. One option is to compare each pair of treatments
in the subpopulation of subjects treated with either of the treatments. This is what we have done
in our real data analysis.
We have also focused on a single time point to evaluate the treatment effect. However, our
methods can be extended to multiple time points, perhaps at the cost of a multiple testing issue.
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Handling time-varying treatments and therefore possible time-varying confounding is more chal-
lenging and beyond the scope of this article; we refer the refer the interested reader to (Bekaert
et al., 2010; Daniel et al., 2013; Moodie et al., 2014; Hernán and Robins, 2019).
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Appendix
A Estimating equation for the AIPTW,AIPCW estimator
For a generic individual with full data O, we denote by mAIPTW the estimating function:
mAIPTW(τ ;O) =Y (τ)
(
A
pi(W ) −
1−A
1− pi(W )
)
+ F1(τ |A = 1,W )
(
1− A
pi(W )
)
− F1(τ |A = 0,W )
(
1− 1−A1− pi(W )
)
−Ψ(τ).
Semi-parametric theory (e.g., (Tsiatis, 2006) - chapter 9, formula 9.34) gives the following aug-
mented estimating equation:
n∑
i=1
1{Ci > Ti ∧ τ}mAIPTW(τ ;Oi)
G(T˜i ∧ τ |Ai,Wi)
−
∫ τ∧T˜i
0
fAIPTW(t, Oi)
G(t|Ai,Wi) dM
C
i (t) = 0
where fAIPTW is an element of the space of real valued functions well-defined on the support of
(T˜ , ∆˜, A,W ). To fully define the estimating equation it remains to define what is fAIPTW. It
is reasonable to choose fAIPTW such the estimator has the smallest asymptotic variance, i.e., its
influence function has the smallest variance. Theorem 10.1 and 10.4 in (Tsiatis, 2006) gives that
this is achieved by taking fAIPTW(t;O) = −E[mAIPTW(τ ;O)|T > t,A,W ]. It follows that:
fAIPTW(t;O) =−
(
E [Y (τ)|T > t,A,W ]
(
A
pi(W ) −
1−A
1− pi(W )
)
−Ψ(τ)
+F1(τ |A = 1,W )
(
1− A
pi(W )
)
− F1(τ |A = 0,W )
(
1− 1−A1− pi(W )
))
,
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where
E[Y (τ)|T > t,A,W ] = P[T ≤ τ, ∆˜ = 1|T > t,A,W ] = P[t < T ≤ τ, ∆˜ = 1|A,W ]
P[T > t|∆˜,W ]
= P[T ≤ τ, ∆˜ = 1|A,W ]− P[T ≤ t, ∆˜ = 1|A,W ]P[T > t|A,W ]
= F1(τ |A,W )− F1(t|A,W )
S(t|A,W ) .
Since: ∫ τ∧T˜
0
1
G(t|A,W )dM
C(t) =
∫ τ∧T˜
0
exp(ΛC(t|A,W ))d(NC(t)− ΛC(t|A,W ))
= 1− 1{C > T˜ ∧ τ}
G(T˜ ∧ τ |A,W ) , (14)
we obtain the augmented estimating equation for the AIPTW estimator:
0 =
n∑
i=1
1{Ci > Ti ∧ τ}
G(T˜i ∧ τ |Ai,Wi)
(
Yi(τ)
(
Ai
pi(Wi)
− 1−Ai1− pi(Wi)
)
+ F1(τ |A = 1,Wi)
(
1− Ai
pi(Wi)
)
−F1(τ |A = 0,Wi)
(
1− 1−Ai1− pi(Wi)
)
−Ψ(τ)
)
+
(
Ai
pi(Wi)
− 1−Ai1− pi(Wi)
)∫ τ∧T˜i
0
F1(τ |Ai,Wi)− F1(t|Ai,Wi)
S(t|Ai,Wi)
1
G(t|Ai,Wi)dM
C
i (t)
+
(
F1(τ |A = 1,Wi)
(
1− Ai
pi(Wi)
)
− F1(τ |A = 0,Wi)
(
1− 1−Ai1− pi(Wi)
)
−Ψ(τ)
)
(
1− 1{Ci > Ti ∧ τ}
G(T˜i ∧ τ |Ai,Wi)
)
,
i.e. denoting I(T˜i, τ |Ai,Wi) =
∫ τ∧T˜i
0
F1(τ |Ai,Wi)−F1(t|Ai,Wi)
S(t|Ai,Wi)
1
G(t|Ai,Wi)dM
C
i (t):
0 =
n∑
i=1
(
Ai
pi(Wi)
− 1−Ai1− pi(Wi)
)(
Yi(τ)1{Ci > Ti ∧ τ}
G(T˜i ∧ τ |Ai,Wi)
+ I(T˜i, τ |Ai,Wi)
)
+ F1(τ |A = 1,Wi)
(
1− Ai
pi(Wi)
)
− F1(τ |A = 0,Wi)
(
1− 1−Ai1− pi(Wi)
)
−Ψ(τ). (15)
Solving equation (15) gives the estimator defined in equation (9). Similar derivations for the IPTW
estimator in presence of censoring lead to equation (8).
B Proof of theorem 1
Correctly specified censoring model: in this case G∗ and M c,∗ are equal to G and M c,
respectively. We use the second notation and show that Ψ̂AIPTW,AIPCW(τ) and Ψ̂AIPTW(τ) have
the same large sample limit. We denote by Ft,i the natural history up to time t for individual i
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where F0,i = (Ai,Wi). For i ∈ {1, . . . , n}, MCi (t) is a martingale satisfying MCi (0) = 0. Since
F ∗1 (τ |Ai,Wi), F ∗1 (t|Ai,Wi), S∗(t|Ai,Wi), and G(t|Ai,Wi) are predictable with respect to F0,i, we
obtain that:
I¯(T˜i, τ |Ai,Wi) =
∫ T˜i∧τ
0
F ∗1 (τ |Ai,Wi)− F ∗1 (t|Ai,Wi)
S∗(t|Ai,Wi)
1
G(t|Ai,Wi)dM
C
i (t)
is a martingale. Using that E[MCi (t)|F0,i] = 0, we get:
E[I¯(T˜i, τ |Ai,Wi)] = E[E[I¯(T˜i, τ |Ai,Wi)|F0,i]] = 0.
Therefore:
E
[
I¯(T˜ , τ |A,W )
(
A
pi∗(W ) −
1−A
1− pi∗(W )
)]
= E
[
E[I¯(T˜ , τ |A,W )|F0]
(
A
pi∗(W ) −
1−A
1− pi∗(W )
)]
= 0
where the outer expectation is taken over the joint distribution of T˜ , A and W . Moreover:
E
[
1{T˜ ≤ τ, ∆˜ 6= 0}
G(T˜ |A,W ) Y (τ)
(
A
pi∗(W ) −
1−A
1− pi∗(W )
)]
= E
[
E
[
1{C > T˜ ∧ τ}
G(T˜ ∧ τ |A,W )
∣∣∣∣∣A,W
]
E
[
Y (τ)
(
A
pi∗(W ) −
1−A
1− pi∗(W )
) ∣∣∣∣∣A,W
]]
= E
[
Y (τ)
(
A
pi∗(W ) −
1−A
1− pi∗(W )
)]
,
where we have used the conditional independent censoring assumption. So limn→∞ Ψ̂AIPTW,AIPCW(τ) =
limn→∞ Ψ̂AIPTW(τ) and 1. and 2. follow from the double robustness of Ψ̂AIPTW(τ).
Misspecified censoring model: We assume that the outcome model and survival model are
correctly specified, i.e., F ∗1 = F1 and S∗ = S. Using equation (14), we obtain:
Yi(τ)1{T˜i ≤ τ, ∆˜ 6= 0}
G∗(T˜i|Ai,Wi)
+
∫ T˜i∧τ
0
F ∗1 (τ |Ai,Wi)− F ∗1 (t|Ai,Wi)
S∗(t|Ai,Wi)G∗(t|Ai,Wi) dM
C,∗
i (t)
=Yi(τ) +
∫ T˜i∧τ
0
F1(τ |Ai,Wi)−F1(t|Ai,Wi)
S(t|Ai,Wi) − Yi(τ)
G∗(t|Ai,Wi) dM
C,∗
i (t)
=Yi(τ) +
∫ T˜i∧τ
0
E[Yi(τ)|Ti > t,Ai,Wi]− Yi(τ)
G∗(t|Ai,Wi) dM
C,∗
i (t).
We now show that the second term has null expectation. Denoting i(t) = E[Yi(τ)|Ti>t,Ai,Wi)]−Yi(τ)G∗(t|Ai,Wi)
and using the conditional independent censoring assumption, we have that E[i(t)|Ti > t,Ai,Wi] =
0. With Ri(t) the at risk process, we can decompose the second term further in two terms:
∫ T˜i∧τ
0
i(t)dMC,∗i (t) =
∫ T˜i∧τ
0
i(t)dMCi (t)+
∫ T˜i∧τ
0
i(t)Ri(t)d
(
ΛC(t|Ai,Wi)− ΛC,∗(t|Ai,Wi)
)
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(16)
The first term in (16) is a mean-zero martingale, and the second term in equation (16) also has
mean zero since
E
[∫ T˜i∧τ
0
Ri(t)i(t)
(
λC(t|Ai,Wi)− λC,∗(t|Ai,Wi)
)
dt
∣∣∣Ai,Wi]
= E
[∫ τ
0
Ri(t)i(t)
(
λC(t|Ai,Wi)− λC,∗(t|Ai,Wi)
)
dt
∣∣∣Ai,Wi]
=
∫ τ
0
E [Ri(t)i(t)|Ai,Wi]
(
λC(t|Ai,Wi)− λC,∗(t|Ai,Wi)
)
dt = 0,
because E [Ri(t)i(t)|Ai,Wi] = E [Ri(t)E[i(t)|Ti > t,Ai,Wi]|Ai,Wi] = 0. So the large sample limit
of the AIPTW,AIPCW estimator is:
lim
n→∞ Ψ̂AIPTW,AIPCW(τ) = E
[
F1(τ |A = 1,W )− F1(τ |A = 0,W )
+
(
A
pi∗(W ) −
1−A
1− pi∗(W )
)(
Y (τ)− F1(τ |A,W ) +
∫ T˜∧τ
0
(t)dMC,∗(t)
)]
= E[F1(τ |A = 1,W )− F1(τ |A = 0,W )]
+ E
[(
A
pi∗(W ) −
1−A
1− pi∗(W )
)(
E[Y (τ)|A,W ]− F1(τ |A,W ) + E
[∫ T˜∧τ
0
(t)dMC,∗(t)
∣∣∣∣∣A,W
])]
= E[F1(τ |A = 1,W )− F1(τ |A = 0,W )]
which also equals Ψ(τ).
C Influence function of the AIPTW,AIPCW estimator
We define the functional ν as a mapping of a set of probability measures to the real numbers such
that for a probability measure P:
ν(P) = ν1(F1, pi, S,G,P)− ν0(F1, pi, S,G,P)
where, for a ∈ {0, 1} and denoting pia(W ) = api(W ) + (1− a)(1− pi(W )), we have:
νa(F1, pi, S,G,P) = E
[
F1(τ |A = a,W )
+ 1{A = a}
pia(W )
Y (τ)− F1(τ |A,W ) + ∫ T˜∧τ
0
F1(τ |A,W )−F1(t|A,W )
S(t|A,W ) − Y (τ)
G(t|A,W ) dM
C(t)
].
where the expectation is relative to the joint distribution of A and W . By denoting Pn the em-
pirical distribution function we have that ν(Pn) = Ψ̂AIPTW,AIPCW(τ). So to obtain the influence
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function of the AIPTW,AIPCW estimator, we only need to derive the influence function associ-
ated with the estimator of νa. Using Slutsky theorem, one can show that νa(Fˆ1n, pˆin, Sˆn, Gˆn,Pn)−
νa(F ∗1 , pˆin, Sˆn, Gˆn,Pn) converges towards νa(Fˆ1n, pi∗, S∗, G∗,Pn)−ν∗a where ν∗a = νa(F ∗1 , pi∗, S∗, G∗,P).
Expanding with respect to each argument leads to:
√
n
(
νa(Fˆ1n, pˆin, Sˆn, Gˆn,Pn)− ν∗a
)
=
√
n
(
νa(Fˆ1n, pi∗, S∗, G∗,P)− ν∗a
)
+
√
n (νa(F ∗1 , pˆin, S∗, G∗,P)− ν∗a) +
√
n
(
νa(F ∗1 , pi∗, Sˆn, G∗,P)− ν∗a
)
+
√
n
(
νa(F ∗1 , pi∗, S∗, Gˆn,P)− ν∗a
)
+
√
n (νa(F ∗1 , pi∗, S∗, G∗,Pn)− ν∗a) + op(1).
We can then calculate the influence function corresponding to each term:
√
n
(
νa(Fˆ1n, pi∗, S∗, G∗,P)− ν∗a
)
= 1√
n
n∑
i=1
I˜Fνa,F1(τ ;Oi) + op(1)
√
n (νa(F ∗1 , pˆin, S∗, G∗,P)− ν∗a) =
1√
n
n∑
i=1
I˜Fνa,pi(τ ;Oi) + op(1)
√
n
(
νa(F ∗1 , pi∗, Sˆn, G∗,P)− ν∗a
)
= 1√
n
n∑
i=1
I˜Fνa,S(τ ;Oi) + op(1)
√
n
(
νa(F ∗1 , pi∗, S∗, Gˆn,P)− ν∗a
)
= 1√
n
n∑
i=1
I˜Fνa,G(τ ;Oi) + op(1)
√
n (νa(F ∗1 , pi∗, S∗, G∗,Pn)− ν∗a) =
1√
n
n∑
i=1
I˜Fνa,P(τ ;Oi) + op(1).
For instance, writing the difference between νa(F ∗1 , pi∗, S∗, G∗,Pn) and ν∗a gives:
I˜Fνa,P(τ ;Oi) = F ∗1 (τ |A = a,Wi)− ν∗a
+ 1{Ai = a}
pia,∗(Wi)
Yi(τ)− F ∗1 (τ |Ai,Wi) + ∫ T˜i∧τ
0
F∗1 (τ |Ai,Wi)−F∗1 (t|Ai,Wi)
S∗(t|Ai,Wi) − Yi(τ)
G∗(t|Ai,Wi) dM
C,∗
i (t)
 .
For I˜Fνa,F1 we use that:
√
n
(
νa(Fˆ1n, pi∗, S∗, G∗,P)− ν∗a
)
=
1√
n
n∑
i=1
E
[
IFF∗1 (τ, a,W ;Oi)
(
1− 1{A = a}
pia,∗(W )
)
+ 1{A = a}
pia,∗(W )
∫ T˜∧τ
0
IFF∗1 (τ,A,W ;Oi)− IFF∗1 (t, A,W ;Oi)
S∗(t|A,W )G∗(t|A,W ) dM
C,∗(t)
∣∣∣∣∣Oi
]
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where pia,∗ indicates the large sample limit of pia and IFF∗1 (t, A,W,Oi) is defined in equation (2).
This leads to:
I˜Fνa,F1(τ ;Oi) =E
[
IFF∗1 (τ, a,W ;Oi)
(
1− 1{A = a}
pia,∗(W )
)
+ 1{A = a}
pia,∗(W )
∫ T˜∧τ
0
IFF∗1 (τ,A,W ;Oi)− IFF∗1 (t, A,W ;Oi)
S∗(t|A,W )G∗(t|A,W ) dM
C,∗(t)
∣∣∣∣∣Oi
]
.
Similar derivations give:
I˜Fνa,pi(τ ;Oi) = −E
[
IFpi∗(W ;Oi)
1{A = a}
(pia,∗(W ))2
(
Y (τ)1{T˜ ≤ τ |∆˜ 6= 0}
G∗(T˜ |A,W ) − F
∗
1 (τ |A,W )
+
∫ T˜∧τ
0
F ∗1 (τ |A,W )− F ∗1 (t|A,W )
S∗(t|A,W )G∗(t|A,W ) dM
C,∗
i (t)
)∣∣∣∣∣Oi
]
I˜Fνa,S(τ ;Oi) = −E
[
1{A = a}
pia,∗(W )
∫ T˜∧τ
0
IFS∗(t, A,W ;Oi)
F ∗1 (τ |A,W )− F ∗1 (t|A,W )
S∗(t|A,W )2G∗(t|A,W ) dM
C,∗(t)
∣∣∣∣∣Oi
]
I˜Fνa,G(τ ;Oi) = −E
[
1{A = a}
pia,∗(W )
(
IFG∗(T˜ , A,W ;Oi)
Y (τ)1{T˜ ≤ τ |∆˜ 6= 0}
G∗(T˜ |A,W )2
+
∫ T˜∧τ
0
IFG∗(t, A,W ;Oi)
F ∗1 (τ |A,W )− F ∗1 (t|A,W )
S∗(t|A,W )G∗(t|A,W )2 dM
C,∗(t)
+
∫ T˜∧τ
0
F ∗1 (τ |A,W )− F ∗1 (t|A,W )
S∗(t|A,W )G∗(t|A,W ) d (IFΛC,∗(t, A,W ;Oi))
)∣∣∣∣∣Oi
]
where IFΛC,∗ denotes the influence function of the cumulative hazard associated to the censoring
mechanism. Furthermore, denoting
IFAIPTW,AIPCW(τ ;Oi) = I˜FAIPTW,AIPCW(τ ;Oi) + φAIPTW,AIPCW(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗)
the influence function of the AIPTW,AIPCW estimator, we get that φAIPTW,AIPCW(τ ;Oi; IFF∗1 , IFpi∗ , IFS∗ , IFG∗)
equals
I˜Fν1,F1(τ ;Oi) + I˜Fν1,pi(τ ;Oi) + I˜Fν1,S(τ ;Oi) + I˜Fν1,G(τ ;Oi)
− I˜Fν0,F1(τ ;Oi)− I˜Fν0,pi(τ ;Oi)− I˜Fν0,S(τ ;Oi)− I˜Fν0,G(τ ;Oi)
and I˜FAIPTW,AIPCW(τ ;Oi) = I˜Fν1,P(τ ;Oi)− I˜Fν0,P(τ ;Oi).
Following the same reasoning as in the section B and using the conditional independence between
the censoring mechanism and the treatment variable, we note that:
• I˜Fνa,F1 = 0 when the treatment and censoring models are correctly specified.
• I˜Fνa,pi = 0 when the outcome and the censoring models are correctly specified.
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• I˜Fνa,S = 0 when the censoring is correctly specified.
• I˜Fνa,G = 0 when the outcome, survival, and censoring models are correctly specified.
So when all models are correctly specified φAIPTW,AIPCW(τ ;Oi, IFF∗1 , IFpi∗ , IFS∗ , IFG∗) = 0 and
IFAIPTW,AIPCW(τ ;Oi) = I˜FAIPTW,AIPCW(τ ;Oi).
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Figure 1 Illustration of the data generating mechanism used in our simulation studies. Shown
are the Aalen-Johansen estimates for the absolute risks of cause 1 in both treatment arms in two
independently drawn datasets (non-randomized and randomized) each of size n=10,000. Panel A:
The treatment effect is zero. In the non-randomized world, the Aalen-Johansen estimate of the 8-
year risk difference is large. Panel B: The treatment has a protective effect. In the non-randomized
world, the Aalen-Johansen estimate of the 8-year risk difference is about zero.
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Figure 2 Simulation setting where there is no treatment effect (panel A of Figure 1). Boxplots
show results of 1000 simulated data sets (each with sample size 500) and each of 4 methods for
estimating the average 10-year risk difference between treated and untreated subjects. Upper left
panel: all regression models (treatment, event of interest, competing risk, censoring) are correctly
specified. Upper right panel: the treatment model is misspecified (missing covariates and missing
quadratic effects). Lower left panel: the event of interest and the competing risk models are
misspecified (missing covariates and missing quadratic effects). Lower right panel: the censoring
model is misspecified (missing quadratic effects).
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Figure 3 Effect of sample size on coverage in a simulation setting where there is no treatment
effect (panel A of Figure 1). The black curve corresponds to the G-formula estimator, the dark grey
curve to the AIPTW,AIPCW estimator using the full influence function to estimate the variance,
and the light gray curve to the AIPTW,AIPCW estimator using only the first term of the influence
function to estimate the variance.
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Figure 4 Illustration in data of Danish registry study. Lines are absolute risk estimates with time-
pointwise 95% confidence limits using G-formula (left panel) and AIPTW,AIPCW (right panel).
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